Nature Neuroscience
October 12, 2026
Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al.
Lysergic acid diethylamide (LSD) is a potent psychedelic with increasing therapeutic interest, yet qualification of target engagement using in vivo neuroimaging has not yet been performed. Using simultaneous positron emission tomography-magnetic resonance imaging technology, we describe multiple brain actions of LSD in seven healthy volunteers blinded to LSD dose received. Here we show that LSD...
Expert Review of Neurotherapeutics
October 8, 2026
Wiesław Jerzy Cubała
Introduction Generalized anxiety disorder (GAD) is a chronic, disabling condition for which currently available pharmacotherapies have delayed onset, incomplete remission rates, treatment-emergent adverse effects and substantial real-world discontinuation. DT120, formerly MM120, is an investigational orally disintegrating tablet formulation of lysergide tartrate being developed as a single-dose...
Translational Psychiatry
October 8, 2026
Friederike Holze, Kristian Larsen, Brice Ozenne et al.
Abstract Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on...
JAMA Network Open
September 29, 2026
Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
Clinical Neuropsychopharmacology and Addiction
September 24, 2026
Giacomo D’andrea, Antonio Inserra, Andrea Miuli et al.
While psychedelic experiences are often reported as positive, adverse psychological reactions can occur. We present the case of a 19-year-old Caucasian male who presented to the ER with suicidal thoughts after taking lysergic acid diethylamide (LSD) alone. He was diagnosed with anxious state associated with panic attacks, and suicidal thoughts without ideation or behaviors. He was admitted to...
bioRxiv (Cold Spring Harbor Laboratory)
September 18, 2026
Aurora Savino, Carla Liaci, Giorgio R. Merlo et al.
preprint
Background Classic psychedelics are serotonergic agents increasingly recognized for their ability to produce rapid and long-lasting therapeutic effects in several neuropsychiatric conditions, yet the molecular mechanisms that translate acute serotonergic perturbation into long-term brain adaptation remain poorly understood. Psychedelic action is commonly attributed to enhanced neuronal...
Psychotropes
September 15, 2026
Zoë Dubus
Durant la première vague d’études occidentales sur les propriétés thérapeutiques du LSD, l’une de ses indications principales dans le modèle « psychédélique » (administration de fortes doses en une à trois séances, surtout utilisée en Amérique du Nord) concerne le traitement de la dépendance à l’alcool. À l’inverse, en Europe, où se développait le modèle « psycholytique » (faibles doses...
The International Journal of Neuropsychopharmacology
September 9, 2026
Todd M Solomon, Robert Barrow, Daniel R Karlin et al.
Abstract Background Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed. Aims & Objectives To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD. Method This phase 2b, multicenter, randomized, double-blind, placebo-controlled study...
The International Journal of Neuropsychopharmacology
September 9, 2026
Friederike Holze, F Müller, Peter Gasser et al.
Abstract Background Anxiety disorders are a major health burden and current treatment options yield unsatisfactory results. Psychedelics, such as lysergic acid diethylamide (LSD) that act via agonism on serotonin 2A receptors, have recently been shown to be effective in the treatment of anxiety symptoms. Aims & Objectives Here, we determine the relationship between the acute experience and...
The International Journal of Neuropsychopharmacology
September 9, 2026
D McCulloch
Abstract Background LSD has recently entered phase 3 clinical trials for anxiety and depressive disorders, yet understanding of its mechanisms of action in the human brain remains incomplete. The serotonin 2A receptor (5-HT2AR) is the critical target for psychedelic effects, but no investigations to date have evaluated the relation between target engagement and systems-level brain function....
Proceedings of the National Academy of Sciences
September 8, 2026
Andrian G Basargin, Andras Domokosa, Joseph J. Hennessey et al.
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in...
Case Reports in Psychiatry
September 3, 2026
Sonali Notani, Vikas Srinivasa, Serena Chaudhry et al.
Hallucinogen persisting perception disorder (HPPD) is a rare psychiatric diagnosis encompassing a range of perceptual disturbances caused by the lingering effects of hallucinogens. There are two major subtypes of the disorder: HPPD I and II. HPPD II is considered a more severe form that is generally longer-term, distressing, and requiring more intense treatment. In the limited available...
The International Journal of Neuropsychopharmacology
September 1, 2026
Gabriella Gobbi
Abstract Background Lysergic acid diethylamide (LSD), a serotonergic psychedelic, has gained renewed interest for its potential anxiolytic effects in clinical trials. However, the neurobiological mechanisms underlying these effects remain poorly understood. Aims & Objectives The goal of this study is to understand the mechanism of action of LSD in animal models by using in vivo...
The International Journal of Neuropsychopharmacology
September 1, 2026
Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
Abstract Background Recent clinical findings have highlighted the therapeutic potential of serotonergic psychedelics, including lysergic acid diethylamide (LSD), in the treatment of affective disorders. Despite these advances, the mechanisms driving their beneficial effects remain partially understood. Aims & Objectives This study sought to assess the prophylactic effects of LSD in rodent...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...
Drug Testing and Analysis
August 27, 2026
Synthesis and Analytical Characterization of 1-(1,2-Dimethylcyclobutane-1-Carbonyl)-Lysergic Acid Diethylamide (1D-LSD) and Differentiation From 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).
Neuroscience of Consciousness
August 20, 2026
Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.
bioRxiv
August 18, 2026
preprint
Tuning in together: LSD enhances inter-brain synchrony and felt connectedness in romantic couples
Med
August 14, 2026
Felix Müller, Anna M Becker, Christopher Böhlke et al.
In Basel, only a few hundred meters from where LSD was first synthesized, we tested LSD-assisted therapy for major depression in a randomized trial comparing two high doses with two low doses, each paired with supportive psychotherapy. This Backstory reflects on treating patients, long dosing days, and what remains uncertain.
Experimental and Clinical Psychopharmacology
August 10, 2026
The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.